medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2016, Número 4

<< Anterior Siguiente >>

Dermatología Cosmética, Médica y Quirúrgica 2016; 14 (4)


Criptococosis cutánea: una revisión

Barbosa-Zamora A, de la Herrán-Millán P, BonifazA

Idioma: Español
Referencias bibliográficas: 66
Paginas: 330-341
Archivo PDF: 247.29 Kb.


RESUMEN

La criptococosis cutánea es una micosis ocasionada por las levaduras capsuladas Cryptococcus neoformans y Cryptococcus gatti. Debido a su inicio se divide en dos tipos: primaria y secundaria. La primera afecta sobre todo a personas con inmunocompetencia, y la segunda a pacientes con algún tipo de inmunosupresión, como vi h-sida y personas con algún transplante. Ambas tienen un amplio espectro de manifestaciones clínicas. El diágnostico se realiza mediante el aislamiento de la levadura y a través de diversas técnicas, entre ellas el uso de tinta china, histopatología, cultivo y pruebas serológicas para identificar el antígeno capsular. El tratamiento se divide en tres estadios; inducción, consolidación y mantenimiento. El estándar de oro es la combinación de anfotericina b más 5-fluorocitosina.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Chayakulkeeree M y Perfect JR. Cryptococcosis, Infect Dis Clin North Am 2006; 20: 507-44.

  2. Bonifaz A. Criptococosis, en Micología médica básica, 4a ed., México 2012; pp. 347-65.

  3. Gullo FP, Rossi SA, Sardi J de C et al. Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment, Eur J Clin Microbiol Infect Dis 2013; 32: 1377-91.

  4. Moretti ML, Resende MR, Lazéra MS et al. Guidelines in cryptococcosis- 2008, Rev Soc Bras Med Trop 2008; 41: 524-44.

  5. Padilla MC, Alonzo L, Novales J et al. Criptococosis cutánea diseminada. Presentación de un caso, Rev Cent Dermatol Pascua 2004; 13: 17-20.

  6. May RC, Stone NR, Wiesner DL et al. Cryptococcus: from environmental saprophyte to global pathogen, Nat Rev Microbiol 2016; 14: 106-17.

  7. Kwon-Chung KJ, Fraser JA, Doering TL et al. Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis, Cold Spring Harb Perspect Med 2014; 4: a019760.

  8. Srikanta D, Santiago-Tirado FH y Doering TL. Cryptococcus neoformans: historical curiosity to modern pathogen, Yeast 2014; 31: 47-60.

  9. Negroni R. Cryptococcosis, Clin Dermatol 2012; 30: 599-609.

  10. Arenas R. Criptococosis, en Micología médica Ilustrada, 5a ed., México 2014; 261-9.

  11. Centers for Disease Control and Prevention, Revised surveillance case definition for hiv infection United States, 2014, mmwr Recomm Rep 2014; 63: 1-10.

  12. Perfect JR. Cryptococcosis: a model for the understanding of infectious diseases, J Clin Invest 2014; 124: 1893-5.

  13. Lin X y Heitman J. The biology of the Cryptococcus neoformans species complex, Annu Rev Microbiol 2006; 60: 69-105.

  14. Morán MA, González GV, Espinoza JP et al. Criptococosis cerebral: análisis de 29 casos en 23 años de autopsias en el Hospital General de México, Rev Lat Patol 2008; 46: 222-7.

  15. Biancheri D, Kanitakis J, Bienvenu AL et al. Cutaneous cryptococcosis in solid organ transplant recipients. Epidemiological, clinical, diagnostic and therapeutic features, Eur J Dermatol 2012; 22: 651-7.

  16. Maziarz EK y Perfect JR. Cryptococcosis, Infect Dis Clin North Am 2016; 30: 179-206.

  17. Moreira TA, Ferreira MS, Ribas RM y Borges AS. Cryptococosis: clinical epidemiological laboratorial study and fungi varieties in 96 patients, Rev Soc Bras Med Trop 2006; 39: 255-8.

  18. Sharma D, Singh N, Kaushal S y Jain S. Isolated cutaneous cryptococcosis in clinically unsuspected idiopathic cd4 lymphocytopenia, J Cytol 2014; 31: 230-2.

  19. Liu Y, Qunpeng H, Shutian X y Honglang X. Fatal primary cutenous cryptococcosis: case report and review of published literature, Ir J Med Sci 2105; doi: 10.1007/s11845-015-1346-x.

  20. Syme RM, Bruno TF, Kozel TR y Mody CH. The capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibody, Infect Immun 1999; 67: 4620-7.

  21. Lin X, Patel S, Litvintseva AP et al. Diploids in the Cryptococcus neoformans serotype A population homozygous for the alpha mating type originate via unisexual mating, PLoS Pathog 2009; 5: 1-18.

  22. Duncan C, Schwantje H, Stephen C et al. Cryptococcus gattii in wildlife of Vancouver Island, British Columbia, Canada, J Wildl Dis 2006; 42: 175-8.

  23. Olivares LR, Martínez KM, Cruz RM et al. Genotyping of Mexican Cryptococcus neoformans and C. gattii isolates by pcr-fingerprinting, Med Mycol 2009; 47: 713-21.

  24. Aye C, Henderson A, Yu H y Norton R. Cryptococcosis. The impact of delay to diagnosis, Clin Microbiol Infect 2016; doi: 10.1016/j. cmi.2016.04.022.

  25. Escandón P, Quintero E, Granados D et al. Isolation of Cryptococcus gattii serotype b from detritus of Eucalyptus trees in Colombia, Biomedica 2005; 25: 390-7.

  26. Hoang LM, Maguire JA, Doyle P et al. Cryptococcus neoformans infections at Vancouver Hospital and Health Sciences Centre (1997-2002): epidemiology, microbiology and histopathology, J Med Microbiol 2004; 53: 935-40.

  27. Castañón-Olivares LR. Complejo Cryptococcus neoformans-cryptococcus gattii, en Méndez-Tovar LJ, López-Martínez R y Hernández-Hernández F. Actualidades en micología médica, México, unam 2008; pp. 263-8.

  28. Steenbergen JN y Casadevall A. The origin and maintenance of virulence for the human pathogenic fungus Cryptococcus neoformans, Microbes Infect 2003; 5: 667-75.

  29. Guerrero A, Jain N, Goldman DL y Fries BC. Phenotypic switching in Cryptococcus neoformans, Microbiology 2006; 152: 3-9.

  30. Casadevall A, Steenbergen JN y Nosanchuk JD. Ready made virulence and dual use virulence factors in pathogenic environmental fungi the Cryptococcus neoformans paradigm, Curr Opin Microbiol 2003; 6: 332-7.

  31. Robertson EJ y Casadevall A. Antibody-mediated immobilization of Cryptococcus neoformans promotes biofilm formation, Appl Environ Microbiol 2009; 75: 2528-33.

  32. Jung WH y Kronstad JW. Iron and fungal pathogenesis: a case study with Cryptococcus neoformans, Cell Microbiol 2008; 10: 277-84.

  33. Pal P, Ray S, Patra SK y Mukherjee D. Disseminated cryptococcosis in an apparently immunocompetent patient presenting with primary intraventricular haemorrhage, bmj Case Rep 2015; doi: 10.1136/bcr- 2015-210250.

  34. Núñez M, Peacock JE Jr y Chin R Jr. Pulmonary cryptococcosis in the immunocompetent host. Therapy with oral fluconazole: a report of four cases and a review of the literature, Chest 2000; 118: 527-534.

  35. Rodríguez LF, Amann R, Verde E et al. Criptococosis diseminada en una paciente portadora de trasplante renal, Nefrol 2005; 25: 73-7.

  36. Du L, Yang Y, Gu K et al. Systemic review of published reports on primary cutaneous cryptococcosis in immunocompetent patients, Mycopathologia 2015; 180: 19-25.

  37. Wang J, Bartelt L, Yu D et al. Primary cutaneous cryptococcosis treated with debridement and fluconazole monotherapy in an immunosuppressed patient: a case report and review of the literature, Case Rep Infect Dis 2015; 2015: 131356.

  38. McKinney JL, Cerio D, Loghmanee C et al. Surgical management of primary cutaneous cryptococcosis after failed medical management, J Hand Microsurg 2015; 7: 116-8.

  39. Leao CA, Ferreira-Paim K, Andrade-Silva L et al. Primary cutaneous cryptococcosis caused by Cryptococcus gattii in a immunocompetent host, Med Mycol 2011; 49: 352-5.

  40. Nascimento E, Bonifácio da Silva ME, Martínez R y Von Zeska Kress MR. Primary cutaneous cryptococcosis in an immunocompetent patient due to Cryptococcus gattii molecular type vgi in Brazil: a case report and review of literature, Mycoses 2014; 57: 442-7.

  41. Lacaz Cda S, Heins-Vaccari EM, Hernández-Arriagada GL et al. Primary cutaneous cryptococcosis due to Cryptococcus neoformans var. gattii serotype b, in an immunocompetent patient, Rev Inst Med Trop Sao Paulo 2002; 44: 225-8.

  42. Leechawengwongs M, Milindankura S, Sahirapongsasuti K et al. Primary cutaneous cryptococcosis caused by Cryptococcus gatti vgii un a tsunami survivor from Thailand, Med Mycol Case Rep 2014; 6: 31-3.

  43. Neuville S, Dromer F, Morin O et al. Primary cutaneous cryptococcosis: a distinct clinical entity, Clin Infect Dis 2003; 36: 337-47.

  44. Severo LC, Zardo IB y Londero AT. Cutaneous cryptococcosis due to Cryptococcus neoformans var. gatti, Rev Iberoam Micol 2001; 18: 200-1.

  45. Jackson NA y Herring DB. Primary capsule-deficient cutaneous cryptococcosis in a sporotrichoid pattern in an immunocompetent host, Cutis 2015; 96: E26-9.

  46. Murad A y Murphy A. Primary cutaneous Cryptococcus neoformans serotype d presenting as painful ulcer and nodules on elbow of an immunocompetent patient, Ir J Med Sci 2014; 183: 691-2.

  47. Christianson J, Engber W y Andes D. Primary cutaneous cryptococcosis in immunocompetent and immunocompromised hosts, Med Mycol 2003; 41: 177-88.

  48. Ni W, Huang Q y Cui J. Disseminated cryptococcosis initially presenting as cellulitis in a patient suffering from nephrotic syndrome, bmc Nephrol 2013; 22: 14-20.

  49. Valente ES, Lazzarin MC, Koech BL et al. Disseminated cryptococcosis presenting as cutaneous cellulitis in an adolescent with systemic lupus erythematosus, Infec Dis Rep 2015; 3: 5743.

  50. Hall JC, Brewer JH, Crouch TT et al. Cryptococcal cellulitis with multiple sites of involvement, J Am Acad Dermatol 1987; 17: 329-32.

  51. Atarguine H, Hocar O, Abbad F y Rais H. Cutaneous cryptococcosis mimicking basal cell carcinoma and revealing systemic involvement in acquired immunodeficiency, J Mycol Med 2015; 25: 163-8.

  52. Kothiwala SK, Prajapat M y Kuldeep CM. Cryptococcal panniculitis in a renal transplant recipient: case report and review of literature, J Dermatol Case Rep 2015; 9: 76-80.

  53. Echaiz JF, Burnham CA y Bailey TC. A case of apophysomyces trapeziformis necrotizing soft tissue infection, Int J Infect Dis 2013; 17: 1240-2.

  54. Fernández-Flores A, Saeb-Lima M y Arenas-Guzmán R. Morphological findings of deep cutaneous fungal infections, Am J Dermatopathol 2014; 36: 531-3.

  55. Taneja J, Bhargava A, Loomba P et al. Cryptococcal granulomas in an immunocompromised hiv -negative patient, Indian J Pathol Microbiol 2008; 51: 553-5.

  56. Dinato SL, Dinato MM, Nakanishi CP et al. Disseminated cutaneous cryptococcosis in a patient with aids, Rev Inst Med Trop S Paulo 2006; 48: 353-8.

  57. Pan B, Chen M, Jia H et al. Multiple subcutaneous abscesses: a rare presentation of cutaneous cryptococcosis, Indian J Dermatol Venereol Leprol 2013; 79: 118-9.

  58. Lazzara M y Joshi A. Disseminated cryptococcosis involving the head and neck, bmj Case Rep 2014; doi:10.1136/bcr-2013-202306.

  59. Béogo R, Andonaba JB, Bamba S et al. Cryptococcosis: a ponttential aetiology of facial ulceration, J Micol Med 2014; 24: 185-8.

  60. Pappalardo MC y Melhem MS. Cryptococcosis: a review of the Brazilian experience for the disease, Rev Inst Med Trop Sao Paulo 2003; 45: 299-305.

  61. Gazzoni AF, Severo CB, Salles EF y Severo LC. Histopathology, serology and cultures in the diagnosis of cryptococcosis, Rev Inst Med Trop Sao Paulo 2009; 51: 255-9.

  62. Coelho C y Casadevall A. Cryptococcal therapies and drug targets: the old, the new and the promising, Cell Microbiol 2016; 18: 792-9.

  63. Liu PY, Yang Y y Shi ZY. Cryptococcal liver abscess: a case report of successful treatment with amphotericin-b and literature review, Jpn J Infect Dis 2009; 62: 59-60.

  64. Perfect JR, Dismukes WE, Dromer F et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America, Clin Infec Dis 2010; 50: 291-322.

  65. Thompson GR, Wiederhold NP, Fothergill AW et al. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans, Antimicrob Agents Chemother 2009; 53: 309-11.

  66. Perfect JR y Bicanic T. Cryptococcosis diagnosis and treat




2020     |     www.medigraphic.com